Anuh Pharma Ltd.
Snapshot View

144.10 -3.20 ▼-2.2%

05 August 2021, 12:35:00 P.M.
Volume: 42,975

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.anuhpharma.com
Financial Indicators
Market Cap 738.15 Cr.
Earnings per share (EPS) 5.67 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 25.96 Trailing Twelve Months Ending 2021-03
Industry PE 32.74 Trailing Twelve Months Ending 2021-03
Book Value / Share 38.04 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.87 Calculated using Price: 147.30
Dividend Yield 1.02 Period Ending 2020-03
No. of Shares Subscribed 5.01 Cr. 50,112,000 Shares
FaceValue 5
Company Profile

Anuh Pharma incorporated in 1960, is one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs). The company is part of the SK Group, which has evolved as a leading importer, exporter, distributor and manufacturer of bulk drugs, chemicals and pharmaceutical formulations.

The company has grown several immensely and earned recognition, besides gaining the trust of a strong customer base. Today, it is one of the largest producers of macrolides in the country.

Anuh Pharma has a product presence in Africa, Asia, Europe, Central/South America and the Middle East. The company's registered office is at E-17/3 and 17/4 MIDC, Tarapur, Boisar, Thane District 401506

Products

  • Macrolides
  • Higher Macrolides
  • Quinolones
  • Chloramphenicol
  • Anti TB Drug
  • Corticosteroids

Recognitions/Certifications

  • Anuh Pharma has received ‘Star Export House’ certification from the Ministry of Commerce and Industry.
  • The company received WHO-GMP certificate for carrying good manufacturing practices.
  • Anuh Pharma has received  ISO 9001:2000 certification

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.17%
1 Week
-2.64%
1 Month
+3.63%
3 Month
+0.35%
6 Month
+11.27%
1 Year
-1.65%
2 Year
+170.76%
5 Year
+45.56%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 19.68 17.31 21.78 23.55 23.44 15.43 11.38 14.87 8.75
Return on Capital Employed (%) 27.74 25.50 32.94 35.13 34.91 21.61 16.31 20.56 10.87
Return on Assets (%) 10.58 9.83 11.75 13.29 14.37 10.58 8.35 10.44 5.06

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 69 76 86 101 119 141 150 165 162
Non Curr. Liab. 0 1 0 0 0 0 0 1
Curr. Liab. 50 60 77 67 72 47 59 75 163
Minority Int.
Equity & Liab. 119 136 163 168 191 187 208 239 326
Non Curr. Assets 37 20 22 24 40 50 54 87 103
Curr. Assets 82 117 142 144 151 138 154 152 223
Misc. Exp. not W/O
Total Assets 119 136 163 168 191 187 208 239 326

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 226 243 266 284 326 206 238 321 307
Other Income 3 2 4 5 4 8 7 5 4
Total Income 229 245 271 289 330 214 245 325 311
Total Expenditure -208 -225 -242 -253 -289 -183 -220 -291 -284
PBIDT 21 20 28 36 41 30 26 35 27
Interest -1 -1 -1 -1 -1 -1 0 -1 -1
Depreciation -1 -2 -2 -3 -2 -2 -2 -2 -7
Taxation -5 -5 -8 -10 -12 -8 -7 -9 -5
Exceptional Items
PAT 13 13 18 22 26 20 17 23 14

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 9 2 15 19 17 26 2 7 49
Cash Fr. Inv. 2 4 -5 -12 -5 -20 2 3 -77
Cash Fr. Finan. -11 -6 -8 -8 -9 -4 -5 -7 22
Net Change 0 0 2 -1 2 2 -1 3 -5
Cash & Cash Eqvt 0 0 2 1 3 5 4 7 2

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 71.78 72.04 72.03 72.04 72.09 71.19 70.46 70.47 70.43
Public 28.22 27.96 27.97 27.96 27.91 28.81 29.54 29.53 29.57
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 26 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the copy of newspaper advertisement with respect to the Notice of 61st Annual General Meeting of the Company through Video Conferencing (VC) / Other Audio Visual Means (OAVM) Book Closure and E-voting Information published in the Financial Express and Mumbai Lakshadeep on Saturday July 24 2021 in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.

Kindly acknowledge the receipt and take the same on record.
Mon, 26 Jul 2021
Board Meeting Intimation for Prior Intimation Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
ANUH PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve Pursuant to the provisions of Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday 6th August 2021 inter alia:
1)To consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June 2021; and
2)To consider any other matter with the permission of the Chairman.
Further pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and in compliance with the Companys Code of Conduct for prevention of Insider Trading the Trading window for dealing in the securities of the Company has been closed for the Designated Persons and their immediate relatives from Wednesday 30th June 2021 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended June 30 2021 i.e. upto Sunday 8th August 2021 (both days inclusive).
Fri, 23 Jul 2021
Reg. 34 (1) Annual Report
Pursuant to the provisions of Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the copy of Annual Report of the Company for the financial year 2020-21 of the Company.

The said Annual Report is also posted on website of the Company www.anuhpharma.com.

Technical Scans View Details

Wed, 04 Aug 2021
High Delivery Percentage High Delivery Percentage
MFI Bearish MFI Bearish
CCI Overbought Zone CCI Overbought Zone
Darkcloud Cover Darkcloud Cover
Tue, 03 Aug 2021
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,527.75 789.50 +0.5%
Divi's Laboratories Ltd. 131,785.24 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. 79,333.82 4,790.90 +0.4%
Cipla Ltd. 75,796.16 947.50 +0.8%
Cadila Healthcare Ltd. 60,170.47 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. 58,468.59 4,065.05 -0.1%
Piramal Enterprises Ltd. 57,915.28 2,593.65 +1.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.40 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2021-03 66.41 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.66 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 31.52 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 28.20 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 388.86 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 43.47 2,593.65 +1.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2021-03 14.18 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.44 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 4.15 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 4.63 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.72 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.69 2,593.65 +1.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 0.10 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,593.65 +1.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 14.13 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,593.65 +1.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 17.85 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,593.65 +1.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 6,969.40 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 19,159.59 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,593.65 +1.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 789.50 +0.5%
Divi's Laboratories Ltd. Consolidated 2020-03 1,984.29 4,944.40 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,790.90 +0.4%
Cipla Ltd. Consolidated 2021-03 2,401.30 947.50 +0.8%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 587.00 -0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,065.05 -0.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,593.65 +1.7%